Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
NOGOB receptor–mediated RAS signaling pathway is a target for suppressing proliferating hemangioma
Wenquan Hu, … , M. Mahmood Hussain, Qing R. Miao
Wenquan Hu, … , M. Mahmood Hussain, Qing R. Miao
Published January 5, 2021
Citation Information: JCI Insight. 2021;6(3):e142299. https://doi.org/10.1172/jci.insight.142299.
View: Text | PDF
Research Article Angiogenesis Vascular biology

NOGOB receptor–mediated RAS signaling pathway is a target for suppressing proliferating hemangioma

  • Text
  • PDF
Abstract

Infantile hemangioma is a vascular tumor characterized by the rapid growth of disorganized blood vessels followed by slow spontaneous involution. The underlying molecular mechanisms that regulate hemangioma proliferation and involution still are not well elucidated. Our previous studies reported that NOGOB receptor (NGBR), a transmembrane protein, is required for the translocation of prenylated RAS from the cytosol to the plasma membrane and promotes RAS activation. Here, we show that NGBR was highly expressed in the proliferating phase of infantile hemangioma, but its expression decreased in the involuting phase, suggesting that NGBR may have been involved in regulating the growth of proliferating hemangioma. Moreover, we demonstrate that NGBR knockdown in hemangioma stem cells (HemSCs) attenuated growth factor–stimulated RAS activation and diminished the migration and proliferation of HemSCs, which is consistent with the effects of RAS knockdown in HemSCs. In vivo differentiation assay further shows that NGBR knockdown inhibited blood vessel formation and adipocyte differentiation of HemSCs in immunodeficient mice. Our data suggest that NGBR served as a RAS modulator in controlling the growth and differentiation of HemSCs.

Authors

Wenquan Hu, Zhong Liu, Valerie Salato, Paula E. North, Joyce Bischoff, Suresh N. Kumar, Zhi Fang, Sujith Rajan, M. Mahmood Hussain, Qing R. Miao

×

Figure 2

NGBR knockdown inhibits the proliferation of HemSCs in vitro.

Options: View larger image (or click on image) Download as PowerPoint
NGBR knockdown inhibits the proliferation of HemSCs in vitro.
(A) NGBR k...
(A) NGBR knockdown was characterized by Western blot and RT-PCR. *P < 0.05 vs. control (siControl) cells (n = 3). (B) Cell proliferation modulated by NGBR deficiency was evaluated by cell proliferation assay after treatment with EGF, FGF2, and VEGF in HemSCs. The results were expressed as fold change relative to the initial cell number. *P < 0.05 vs. control (siControl) cells. #P < 0.05 vs. control (siControl) cells treated with EGF, FGF2, and VEGF (n = 4), 3 repeats. (C) NGBR knockdown inhibited BrdU incorporation in HemSCs treated with growth factors. Cells treated with EGF, FGF2, and VEGF displayed more BrdU-positive cells than control groups. NGBR knockdown abolished EGF-induced, FGF2-induced, and VEGF-induced BrdU incorporation. Quantitative analysis of BrdU-positive cells was determined by ImageJ software. *P < 0.05 vs. control (siControl) cells. #P < 0.05 vs. control (siControl) cells treated with EGF, FGF2, and VEGF (n = 4), 3 repeats. (D) HemSCs expressing FUCCI cell cycle markers were transiently transfected with siControl or siNGBR. After 24 hours, the cells were fixed, and the images were taken with a confocal microscope. Quantitative analysis of G1 phase cells was determined by ImageJ software. *P < 0.05 vs. control (siControl) cells (n = 3), 3 repeats. (E) HemSCs transfected with siNGBR underwent G1 phase arrest. The cell cycle distribution was analyzed by flow cytometry using PI staining. The percentage of different cell cycle phases presented in histogram form has been summarized in the bar graph (right). *P < 0.05 vs. control (siControl) cells (n = 3), 3 repeats. (F) Protein levels of NGBR, p21, p53, cyclin D1, RB1, and phosphorylated RB1 in HemSCs treated with siControl and siNGBR were determined by Western blot. *P < 0.05 vs. control (siControl) cells (n = 3). Statistical analyses: 2-tailed unpaired Student’s t test (A, D, E, and F) and 1-way ANOVA with Bonferroni’s post hoc test (B and C); data are expressed as mean ± SEM. HemSCs, hemangioma stem cells; NGBR, NOGOB receptor; siControl, control siRNA; siNGBR, NGBR siRNA; FUCCI, fluorescence ubiquitination cell cycle indicator; RB1, retinoblastoma; PI, propidium iodide.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts